FOLH1 and cancer: Despite the remarkable efficacy of PSMA-targetedradiopharmaceutical therapy (RPT) in imaging and PSA (prostate-specificantigen) response, the current clinical data are showing certain limitations,including cancer recurrence and progression, and radiation-inducedtoxicity.